第8回日経・FT感染症会議 - NIKKEI FT
Communicable Diseases Conference

開催日 2021年10月27日(水)-28日(木)参加料無料 事前登録抽選制 dates October 27 (Wed.) -28 (Thu.) 2021

当会議は、日経チャンネルで2022年10月中旬までアーカイブ映像をご覧いただけます。

Click here to watch / ご視聴はこちら

Program - プログラム

DAY1October 27(Wed.) 10月27日(水)

*Program contents are subject to change without prior notice.
*Japanese/English simultaneous interpretation will be available.

*プログラム内容は事前の予告なく変更になる場合がございます。
*この会議では日英同時通訳が利用できます。

8:30-8:40

Opening Remarks開会挨拶

Ms. Yuko SHIOZAKI

Managing Executive Officer,
Media Business,
Nikkei Inc.

Ms. KOIKE Yuriko

Governor of Tokyo

Dr. Tedros Adhanom GHEBREYESUS

Director-General,
World Health Organization (WHO)

8:40-9:05

Agenda 1 - Introduction : Aims and goals of the 8th Conference議題1:第8回会議の意義付け

Dr. Shigeru OMI, MD, PhD

President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
World Health Organization (WHO), Regional Office for Western Pacific

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Mr. Manabu YOSHIDA

Vice-Minister
Ministry of Health, Labour and Welfare

9:05-10:15

Agenda 2 - Key discussion issue①Olympic/Paralympic games under pandemic議題2:重点テーマ①東京五輪・パラリンピック/水際対策

Moderator

Dr. Kazunari ASANUMA, MD, PhD

Senior Assistant Minister for Health Security and Technology,
Minister's Secretariat,
Ministry of Health, Labour and Welfare

Click here for a list of discussers

  • Dr. Nobuhiko OKABE, MD, Ph.D.

    Director General,
    Kawasaki City Institute for Public Health

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Dr.Kazunari TANAKA, MD, PhD

    Director of Shizuoka City public health center

  • Hidemasa NAKAMURA, MPP

    Games Delivery Officer, GDO
    Tokyo 2020

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Dr. Richard H. KASZYNSKI

    Co-founder and Director
    Stanford Solutions, Stanford Medical School

10:25-12:05

Agenda 3 - Key discussion issue②Tests議題3:重点テーマ②検査

Moderator

Prof. Dr. Kazutoshi NAKASHIMA, MD, PhD

Professor
Department of Health Science, Faculty of Sports and Health Science,
Daito Bunka University

Click here for a list of discussers

  • Kazuya OMI, Ph.D.

    Executive Officers (Research and Development)
    H.U. Group Holdings, Inc.,
    President
    H.U. Group Research Institute G.K.,

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Mr. Kenichi KANEKO

    CEO
    ICheck Co,.Ltd.

  • Dr. Masaaki KITAJIMA, PhD

    Associate Professor
    Division of Environmental Engineering,
    Faculty of Engineering, Hokkaido University

  • Dr. Makoto KURODA, PhD

    Director
    Pathogen Genomics Center,
    National Institute of Infectious Diseases

  • Yasuyuki SAHARA, MD, MPH

    Director General Health Service Bureau
    Ministry of Health, Labour and Welfare

  • Prof. Dr. Eiichiro SANDO, MD, PhD, FACP

    Professor,
    Department of General Internal Medicine and Clinical Infectious Diseases
    Fukushima Medical University / Kita-Fukushima Medical Center

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Dr. Motoi SUZUKI, MD PhD

    Director
    Center for Surveillance, Immunization,
    and Epidemiologic Research
    National Institute of Infectious Diseases

  • Dr. Yoshihiro TAKAYAMA, MD

    Deputy director
    Division of Infectious Diseases
    Okinawa Chubu Hospital

  • Mr. TAJIMA Hideji

    President
    Precision System Science Co., Ltd.

  • Dr. Kiyosu TANIGUCHI, MD,PhD.

    Director General
    National Hospital Organization Mie National Hospital

  • Mr. Mitsuru TANIGUCHI

    Executive Vice President
    LS Business
    Sysmex Corporation

  • Dr. Hiroyuki NODA, MD, PhD

    Office for Novel Coronavirus Disease Control,
    Office for Pandemic Influenza and New Infectious Diseases & Coordination Office of Measures on Emerging Infectious Disease / Councilor
    Cabinet Secretariat

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

12:10-13:00 Special Session 1特別セッション①

ICheck ICheck

Effectiveness of Antigen testing in the prevention of COVID-19 infectious diseasesCOVID-19感染症対策における抗原検査の有効性

Moderator

Ms. Hitomi SHIMATANI

CEO
Eye-Land.Co.,ltd.
Outside Director / Ambassador
ICheck Co.,Ltd.

Click here for a list of discussers

  • Dr. Kiyoshi KUROKAWA

    Chair, Hideyo Noguchi Africa Prize Committee
    Chair of the Board, Health and Global Policy Institute
    Professor Emeritus, the University of Tokyo, National Graduate Institute for Policy Studies and Tokai University

  • Mr. Koichi YAMADA

    Senior Vice President
    FUJIFILM Toyama Chemical Co.,Ltd.

  • Michael CHEN, MD

    Associate Professor of Perioperative Medicine
    Director of Pediatric Neuroanesthesia
    Co-chair of Pharmacy & Therapeutics, LPCH
    Stanford University

  • Dr. Richard H. KASZYNSKI

    Co-founder and Director
    Stanford Solutions, Stanford Medical School

13:10-14:00 Special Session 2特別セッション② Breakout Session A分科会 A

Daiichi Sankyo Co., Ltd., 第一三共

Collaboration among Stakeholders to Implement the “Strategy for Strengthening Vaccine Development and Production Systems”「ワクチン開発・生産体制強化戦略」の実現に向けたステークホルダー連携

Moderator

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Mr. Masayuki IMAGAWA, M.B.A., M.Sc., R.Ph.

    Head, Japan Vaccine Business Unit,
    Takeda Pharmaceutical Co., Ltd
    Chief Executive,
    Japan Association of Vaccine Industries

  • Norio TAMURA, MBA, Ph.D

    Vice President
    Integrated Disease Care Division ,Vaccine Business Department,
    SHIONOGI & CO., LTD.

  • Mr. Toru TANZAWA

    Vice President
    Vaccine Business Department Japane Business Unit
    Daiichi Sankyo Co., Ltd.

  • Tomonori NAKAYAMA, PhD

    Health Policy Director
    National Health Policy Secretariat /
    Cabinet Office, Government of Japan

  • Mr. Takeshi NARUSE

    Managing Executive Officer, Senior Manager, Production Division
    KM Biologics Co., Ltd.

  • Mr. Seiichi MURAKAMI

    DIRECTOR
    THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY

Saraya Co., Ltd., サラヤ

No One Left Behind- Infection Control in Nursing and Welfare Facilities in a Post-COVID World.
- Thinking about the role of Industry, Government, Academia, Medical and Nursing Careポストコロナを見据えた介護福祉施設の感染対策
~No One Left Behindに向けて、産官学医介の役割を考える~

Moderator

Mr. Michikazu KOSHIBA

MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.
Head, Center on Global Health Architecture/General Manager, Social Impact Partnership Business Dept.

Click here for a list of discussers

  • PhD Takayuki OHISHI

    Department of Infection Control and Prevention
    Saiseikai Yokohamashi Tobu Hospital

  • Ms. Hitomi KUROSU, RN, MS, PhD

    National Institute of Infectious Diseases (NIID)
    AMR Research Center

  • Yoko YOSHIDA, PhD

    Medical Business Division / Managing Director
    Saraya Co., Ltd.

14:10-15:00 Special Session 3特別セッション③ Breakout Session B分科会 B

KM Biologics/Meiji Seika Pharma Co., Ltd., KMバイオロジクス/Meiji Seika ファルマ

Japan-made inactivated COVID-19 vaccine ~positioning of the vaccine and scenario for the earliest supply~国産不活化COVID-19ワクチン~ポジショニングと早期供給へのシナリオ~

Moderator

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Mr. Daikichiro KOBAYASHI

    President and Representative Director
    Meiji Seika Pharma Co., Ltd.

  • Kengo SONODA, PhD

    Development Department / General Manager
    KM Biologics Co., Ltd.

  • Mr. Toshiaki NAGASATO

    President and Representative Director
    KM Biologics Co.,Ltd

FUMAKILLA LIMITED フマキラー

Problems with insecticide resistance development: How to use the discovery of mutant mosquitoes to vector control殺虫剤抵抗性発達をめぐる問題:突然変異蚊の発見を防除に活かすには

Moderator

Prof. Noboru MINAKAWA Ph.D.

Institute of Tropical Medicine, Nagasaki University
Professor,

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH

    Assistant Minister for Global Health and Welfare,
    Ministry of Health, Labour and Welfare

  • Shinji KASAI, Ph.D.

    Director,
    Department of Medical Entomology
    National Institute of Infectious Diseases

  • Ms. Fumiko KIMOTO

    Research & Development Division Researcher
    Research & Development Department
    Fumakilla Limited

  • PhD. Tomonori SASAKI

    OFFICE MANAGER
    RESEARCH & DEVELOPMENT DEPARTMENT
    FUMAKILLA LIMITED

15:10-16:40

Agenda 4 - Key discussion issue③Vaccines議題4:重点テーマ③ワクチン

Moderator

Prof. Yasuhiro SUZUKI

Vice-Rector
International University of Health & Welfare

Click here for a list of discussers

  • Dr. ARAKI Hiroto, MD, PhD

    Counsellor
    Cabinet Office, Government of Japan

  • Ken J. ISHII, M.D., Ph.D.

    Professor,
    Division of Vaccine Science, Department of Microbiology and Immunology
    The Institute of Medical Science, The University of Tokyo

  • Mr. Masayuki IMAGAWA, M.B.A., M.Sc., R.Ph.

    Head, Japan Vaccine Business Unit,
    Takeda Pharmaceutical Co., Ltd
    Chief Executive,
    Japan Association of Vaccine Industries

  • Prof. Yoko URYUHARA, MBA, PhD

    Associate Professor,
    Faculty of Commerce, Doshisha University
    Director, Social Marketing Research Centre

  • Dr. Satoshi EZOE, MD,MPH,MPA,PhD

    Director,
    Global Health Policy Division, International Cooperation Bureau
    Ministry of Foreign Affairs

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Dr. Junko SATO, PhD

    Office Director,
    Office of International Cooperation,
    Pharmaceuticals and Medical Devices Agency (PMDA)

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • TACHIYA Hidekiyo,MD

    Mayor of Soma City

  • Isao TESHIROGI, Ph.D

    President and CEO
    Shionogi & Co., Ltd.

  • Dr. NAKATANI Yukiko,MD,PhD

    Director, Blood and Blood Products Division, MHLW
    Counselor, Vaccination Task Force for COVID-19, Cabinet Secretariat
    Ministry of Health , Labour and Welfare(MHLW)

  • Mr. Toshiaki NAGASATO

    President and Representative Director
    KM Biologics Co.,Ltd

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Dr. Sunao MANABE, DVM, PhD

    Representative Director, President and CEO
    Daiichi Sankyo Co., Ltd.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Prof. Kaori MUTO

    Professor / Department of Public Policy, Human Genome Center
    The Institute of Medical Science, The University of Tokyo

  • Prof. Dr. Hiroyuki MORIUCHI, MD, PhD

    Professor and Head
    Department of Pediatrics
    Nagasaki University Graduate School of Biomedical Sciences / School of Tropical Medicine and Global Health

  • Dr. Yasuhiro YASUTOMI, DVM, PhD

    Director, Tsukuba Primate Research Center, National Institute of Biomedical Innovation, Health and Nutrition (NIBIOHN)
    Professor, Division of Immunoregulation, Department of Molecular and Experimental Medecine, Mie University Graduate School of Medicine

  • Prof. Koji WADA, MD, MSc, PhD

    Professor
    Graduate School of Medicine
    International University of Health and Welfare

  • Mr. Thomas B. CUENI

    Director General
    International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

16:50-18:00

Agenda 5 -Key discussion issue④Medical care supplies議題5:重点テーマ④医療提供体制

Moderator

Dr. Akifumi IMAMURA, M.D.

Director
Department of Infectious Diseases
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

Click here for a list of discussers

  • INOKUCHI Masataka,M.D.,Ph.D.

    Vice President
    Tokyo Medical Association

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Director
    National Center for Global Health and Medicine Hospital
    Disease Control and Prevention Center

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Dr. Tetsuya SAKAMOTO, MD, PhD

    Director of Hospital,Professor of Emergency Medicine
    Teikyo University Hospital

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Prof. Yasuhiro SUZUKI

    Vice-Rector
    International University of Health & Welfare

  • Manabu SUMI, MD, MPH, PhD

    Director,
    Regional Medical Care Planning Division, Health Policy Bureau
    Ministry of Health, Labour and Welfare

  • Dr. Yoshihiro TAKAYAMA, MD

    Deputy director
    Division of Infectious Diseases
    Okinawa Chubu Hospital

  • Prof. Hiroshi NISHIURA, M.D., Ph.D.

    Professor
    Kyoto University

  • Itaru NISHIZUKA, MD, PhD, MPH

    Director General
    Sumida City Public Health Center

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

18:10-19:00 Special Session 4特別セッション④ Breakout Session C分科会 C

FUJIFILM Toyama Chemical Co., Ltd. 富士フイルム富山化学

COVID-19 Treatment Strategy By Antiviral Drug Early InterventionCOVID-19治療における抗ウイルス剤早期介入の意義

Moderator

Prof. Nahoko SHINDO, MD, PhD

Senior Advisor,
WHO Health Emergencies Programme (WHE),
World Health Organization

Click here for a list of discussers

  • Dr. Yohei DOI, MD, PhD

    Departments of Microbiology and Infectious Diseases (FHU) / Division of Infectious Diseases (UPitt)
    Fujita Health University

  • Mr. Koichi YAMADA

    Senior Vice President
    FUJIFILM Toyama Chemical Co.,Ltd.

  • Armand BALBONI, MD, PhD

    Chief Executive Officer
    Appili Therapeutics

  • Yoav GOLAN, MD

    Chief Medical Officer
    Appili Therapeutics

  • Dr. Richard H. KASZYNSKI

    Co-founder and Director
    Stanford Solutions, Stanford Medical School

The Research Foundation for Microbial Diseases of Osaka University 阪大微生物病研究会

From Risk Management to Health and Productivity Management; Infectious Disease Control in Companies for After-Pandemicリスク管理から健康経営へ ポストコロナを見据えた、企業の感染症対策

Moderator

Mr. Hisahiko YANO

Senior Staff Writer Editional Bureau
Nikkei Inc.

Click here for a list of discussers

  • Dr. Kunio OKADA

    President
    Non-Profit Organization Kenkokeiei

  • Aya KAYEBETA MD

    Director,
    Disease Prevention and Information/
    Data Management Section, Infectious Disease Control Division, Bureau of Social Welfare and Public Health
    Tokyo Metropolitan Government

19:10-19:40

Special Agenda:How International Consortium Accelerates Drug Development for COVID-19特別企画:COVID-19の医薬品開発加速に向けた国際協力 – そのあるべき姿

Moderator

Mr. Hisahiko YANO

Senior Staff Writer Editional Bureau
Nikkei Inc.

Click here for a list of discussers

  • Dr. Kiyoshi KUROKAWA

    Chair, Hideyo Noguchi Africa Prize Committee
    Chair of the Board, Health and Global Policy Institute
    Professor Emeritus, the University of Tokyo, National Graduate Institute for Policy Studies and Tokai University

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Prof. Yasuhiro SUZUKI

    Vice-Rector
    International University of Health & Welfare

  • Mr. Omar QANDEEL

    Chairman
    Nippon Trading EST

DAY2October 28(Thu.) 10月28日(木)

*Program contents are subject to change without prior notice.
*Japanese/English simultaneous interpretation will be available.

*プログラム内容は事前の予告なく変更になる場合がございます。
*この会議では日英同時通訳が利用できます。

8:15-8:20

Message from the Guest来賓メッセージ

H.E. Mr. Peter TAN Hai Chuan

Ambassador Extraordinary and Plenipotentiary of the Republic of Singapore

8:20-9:40

Agenda 6 - Key discussion issue⑤Utilizing ICT and bigdata議題6:重点テーマ⑤データ活用

Moderator

Mr. Michikazu KOSHIBA

MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.
Head, Center on Global Health Architecture/General Manager, Social Impact Partnership Business Dept.

Click here for a list of discussers

  • Prof. Yoko URYUHARA, MBA, PhD

    Associate Professor,
    Faculty of Commerce, Doshisha University
    Director, Social Marketing Research Centre

  • Prof. Ken OSAKA, MD, PhD, MPH

    Professor
    International Research Institute of Disaster Science. School of Dentistry.
    Tohoku University

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Shumpei TAKEMORI, Ph.D.

    Chairman
    Mitsubishi UFJ Research and Consulting Co., Ltd.

  • Prof. Dr. Kazutoshi NAKASHIMA, MD, PhD

    Professor
    Department of Health Science, Faculty of Sports and Health Science,
    Daito Bunka University

  • Prof. Hiroshi NISHIURA, M.D., Ph.D.

    Professor
    Kyoto University

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Dr. Takanori FUJITA, MD, JD

    Specially Appointed Associate Professor
    Department of Health Policy and Management,
    Keio University School of Medicine

  • Dr. Hideo MAEDA,MD, MPH

    Director,
    Tokyo Kita City Public Health Center

  • Kuniaki MIYAKE MD,MSc

    CMO,CHO
    DeNA

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Prof. Kaori MUTO

    Professor / Department of Public Policy, Human Genome Center
    The Institute of Medical Science, The University of Tokyo

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

  • Mr. Shoji WATANABE

    Director-General,
    Office for Novel Coronavirus Disease Control, Cabinet Secretariat,
    Government of Japan

9:50-10:50

Agenda 7 - Key discussion issue⑥Nation’s decision making議題7:重点テーマ⑥国の意思決定

Moderator

Prof. Dr. Izuru MAKIHARA

Professor
Research Center for Advanced Science and Technology, University of Tokyo

Click here for a list of discussers

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Dr. KANO Mitsunobu, MD/PhD

    Vice Executive Director and Professor
    Okayama University
    Council Member, Science Council of Japan
    Science and Techonology Co-Advisor to the Minister of Foreign Affairs of Japan

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Dr. Yosuke SUNAHARA

    Kobe University
    Graduate School of Law

  • Prof. Keizo TAKEMI

    Member of the House of Councillors,
    Vice-Chairperson, General Assembly of Party Members of the House of Councillors
    Chairperson, Special Committee on Global Health Strategy of LDP
    Acting-Chairperson, Headquarters for Novel Coronavirus of LDP
    Chairperson, Subcommittee on Governance for Infectious Diseases of LDP
    WHO Goodwill Ambassador for Universal Health Coverage
    Senior Fellow, Japan Center for International Exchange (JCIE)
    Visiting Professor at Nagasaki University

  • Takako NOJIRI, MD

    Senior Technical Director for Welfare Health Department,
    Wakayama Prefecture Government

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Dr. Yoichi FUNABASHI

    Co-founder and Chairman
    Asia Pacific Initiative

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Mr. Yasuhide YAMADA

    Former Director-General of Coordination Office of Measures on Emerging Infectious Diseases, Cabinet Secretariat, Government of Japan
    Executive Officer, SHIMIZU CORPORATION

11:00-11:50 Special Session 5特別セッション⑤ Breakout Session D分科会 D

SHIONOGI 塩野義製薬

Urgent need for measures against AMR threat as silent pandemicsAMRのサイレントパンデミックとしての脅威と喫緊な対策の必要性

Moderator

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH

    Assistant Minister for Global Health and Welfare,
    Ministry of Health, Labour and Welfare

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Director
    National Center for Global Health and Medicine Hospital
    Disease Control and Prevention Center

  • Dr. Yohei DOI, MD, PhD

    Departments of Microbiology and Infectious Diseases (FHU) / Division of Infectious Diseases (UPitt)
    Fujita Health University

  • Dr. Yoshinori YAMANO, Ph.D.

    Chief Scientific Officer for Infectious Diseases,
    Pharmaceutical Research Division,
    SHIONOGI & CO., LTD.

SYSMEX CORPORATION シスメックス

Innovation in diagnostics for emerging and reemerging communicable diseases新興・再興感染症に対する検査のイノベーション

Click here for a list of discussers

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Director
    National Center for Global Health and Medicine Hospital
    Disease Control and Prevention Center

  • Dr. Shigeyuki KANO, MD, PhD, Hon PhD (Mahidol)

    Director,
    Department of Tropical Medicine and Malaria
    Research Institute, National Center for Global Health and Medicine (NCGM)

  • Masatoshi WAKUI, M.D., Ph.D.

    Associate Professor
    Department of Laboratory Medicine
    Keio University School of Medicine

12:00-12:50 Special Session 6特別セッション⑥ Breakout Session E分科会 E

Tokyo Metropolitan Government 東京都

COVID-19 and risk communicationCOVID-19とリスクコミュニケーション

Moderator

Prof. Yumiko NARA, PhD

Professor,
Graduate School of Human Life and Health Sciences Program,
The Open University of Japan

Click here for a list of discussers

  • Dr. Yoshihiro OTA, M.D., MBA

    Chairman of the Board of Trustees
    Nagoya Memorial Hospital and Foundation

  • Prof. Mitsuo KAKU, MD, PhD

    Chair of Tokyo iCDC , Tokyo Metropolitan Government.
    Professor, Division of Infectious Diseases and Infection Control, Faculty of Medicine, Tohoku Medical and Pharmaceutical University

  • Mr. Junichi TAKI

    Editorial Bureau, Senior Staff Writer
    Nikkei Inc.

  • Prof. Kaori MUTO

    Professor / Department of Public Policy, Human Genome Center
    The Institute of Medical Science, The University of Tokyo

Pfizer Japan Inc. ファイザー

The economic value of AMR countermeasures and the need for new antimicrobialsAMR対策の経済的な価値と新規治療薬の必要性

Moderator

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH

    Assistant Minister for Global Health and Welfare,
    Ministry of Health, Labour and Welfare

  • Prof. Kazumasa OGURO

    Professor
    Hosei University

  • Dr. Hiroyuki NODA, MD, PhD

    Office for Novel Coronavirus Disease Control,
    Office for Pandemic Influenza and New Infectious Diseases & Coordination Office of Measures on Emerging Infectious Disease / Councilor
    Cabinet Secretariat

  • Dr. Akihisa HARADA, M.D., Ph.D.

    President & Representative Director
    Pfizer Japan Inc.

  • Prof. Tetsuya MATSUMOTO, MD, PhD

    Chief Professor
    Department of Infectious Diseases /
    International University of Health and Welfare

13:00-13:50 Special Agenda -The Japan Pharmaceutical Manufacturers Association (JPMA)特別企画 日本製薬工業協会

Preparedness for Emerging and Re-emerging Infectious Diseases, Including Antimicrobial Resistance (AMR)
---Expectations for economic security and control tower function---
薬剤耐性菌(AMR)を含む新興・再興感染症への備え
~必要な経済安全保障戦略と司令塔機能~

Moderator

Prof. Nahoko SHINDO, MD, PhD

Senior Advisor,
WHO Health Emergencies Programme (WHE),
World Health Organization

Click here for a list of discussers

  • Mr. Yasushi OKADA

    Chairman
    Japan Pharmaceutical Manufacturers Association

  • Mr. Katsufumi JO

    Executive Director
    Japan Agency for Medical Research and Development

  • Dr. Yohei DOI, MD, PhD

    Departments of Microbiology and Infectious Diseases (FHU) / Division of Infectious Diseases (UPitt)
    Fujita Health University

  • Mr. Atsuo YAGAMI

    Director-General
    National Health Policy Secretariat, Cabinet Office

13:55-15:35

Agenda 8 - PPP projects from the Conference and their future issues議題8:会議発P3プロジェクトの進捗と課題

Moderator

Prof. KITA Kiyoshi

Dean and Professor,
School of Tropical Medicine and Global Health,
Nagasaki University

Mr. Ryoji NORITAKE

CEO and Board Member,
Health and Global Policy Institute (HGPI)

Mr. Mitsuru MIYATA

CEO
Miyata Institute of Technologies,K.K.

Click here for a list of discussers

  • Hajime INOUE, MD, MPH, DrPH

    Assistant Minister for Global Health and Welfare,
    Ministry of Health, Labour and Welfare

  • Hayato URABE, PhD, MPIA

    Senior Director, Investment Strategy, Portfolio Development & Innovations
    Global Health Innovative Technology Fund (GHIT Fund)

  • Norio OHMAGARI, M.D., M.Sc., Ph.D.

    Director
    National Center for Global Health and Medicine Hospital
    Disease Control and Prevention Center

  • Prof. Kazumasa OGURO

    Professor
    Hosei University

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Akira KANEKO, MD, PhD, DTM&H

    Professor,
    Department of Parasitology,
    Osaka City University Graduate School of Medicine

  • Dr. Shigeyuki KANO, MD, PhD, Hon PhD (Mahidol)

    Director,
    Department of Tropical Medicine and Malaria
    Research Institute, National Center for Global Health and Medicine (NCGM)

  • Prof. Osamu KUNII, MD, MPH, PhD,

    Head, Strategy, Investment and Impact Division (SIID)
    The Global Fund to Fight AIDS, Tuberculosis and Malaria

  • Mr. Shinichi KOHGUCHI

    Senior Stewardship Officer
    Stewardship Development Department,
    Sumitomo Mitsui Trust Asset Management Co.,Ltd.

  • Mr. Yusuke SARAYA

    President
    Saraya Co., Ltd.

  • Ms. Takuko SAWADA

    Director of the Board, Executive Vice President
    Head, Integrated Disease Care Division
    Shionogi & Co., Ltd.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Prof. Dr. Tomohiko SUGISHITA

    Department of International Affairs and Tropical Medicine
    Tokyo Women’s Medical University

  • Dr. Kazuhiro TATEDA, MD, PhD

    professor
    Department of Microbiology and Infectious Diseases /
    Toho University School of Medicine

  • Yasunori TAWARAGI, PhD

    Environmental Management and Global Health Group Sustainability Promotion Department
    DAIICHI SANKYO CO.,LTD.

  • Mr. Susumu TSUBAKI

    Representative Director / CEO
    Asia Africa Investment and Consulting Pte. Ltd.(AAIC)

  • Dr. Hiroyuki NODA, MD, PhD

    Office for Novel Coronavirus Disease Control,
    Office for Pandemic Influenza and New Infectious Diseases & Coordination Office of Measures on Emerging Infectious Disease / Councilor
    Cabinet Secretariat

  • Mr. Yutaka HADA

    Chief Secretariat
    Japan Business Council for Africa

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Prof. Kenji HIRAYAMA, MD. Ph.D.

    School of Tropical Medicine and Global Health
    Nagasaki University

  • Mr. Yoshihide HIRUTA

    Director of International Cooperation, International Business Management, Global Management
    Sysmex Corporation

  • Toshihiro HORII, PhD

    Endowed Professor
    Department of Malaria Vaccine Development /
    Research Institute for Microbial Diseases,
    Osaka University

  • Prof. Toshihiro MITA, M.D., PhD

    Professor and Chair,
    Department of Molecular and Cellular Parasitology,
    Juntendo University School of Medicine

  • Mr. Hajime WATARI

    Director and Senior Vice President, GM of Global Business
    EIKEN Chemical Co.,Ltd.

  • Professor Dame Sally DAVIES

    UK Government Special Envoy on Antimicrobial Resistance
    UK Department of Health and Social Care

  • Dr. John NKENGASONG MSc, PHD

    Director
    Africa Centers for Disease Control and Prevention (CDC)- African Union Commission

  • Dr. Amit N THAKKER

    Chairman
    Africa Health Business

15:40-16:05

Nikkei Asia Talk Session - Evaluating COVAX日経アジアトークセッション:COVAXはどう動いたか

Moderator

Mr. Michael PEEL

Executive editor
Nikkei Asia

Click here for a list of discussers

  • Ambassador Keiichi ONO

    Assistant Minister
    Director-General and Ambassador for Global Issues
    Ministry of Foreign Affairs of Japan

  • Dr. Seth BERKLEY

    CEO
    Gavi, the Vaccine Alliance

  • Dr Richard HATCHETT

    CEO
    CEPI

16:10-17:20

Summary Sessionサマリーセッション

Click here for a list of discussers

  • Dr. Kazunari ASANUMA, MD, PhD

    Senior Assistant Minister for Health Security and Technology,
    Minister's Secretariat,
    Ministry of Health, Labour and Welfare

  • Dr. Akifumi IMAMURA, M.D.

    Director
    Department of Infectious Diseases
    Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

  • Prof. Yoko URYUHARA, MBA, PhD

    Associate Professor,
    Faculty of Commerce, Doshisha University
    Director, Social Marketing Research Centre

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Dr. KANO Mitsunobu, MD/PhD

    Vice Executive Director and Professor
    Okayama University
    Council Member, Science Council of Japan
    Science and Techonology Co-Advisor to the Minister of Foreign Affairs of Japan

  • Prof. KITA Kiyoshi

    Dean and Professor,
    School of Tropical Medicine and Global Health,
    Nagasaki University

  • Mr. Michikazu KOSHIBA

    MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.
    Head, Center on Global Health Architecture/General Manager, Social Impact Partnership Business Dept.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Prof. Yasuhiro SUZUKI

    Vice-Rector
    International University of Health & Welfare

  • Mr. Junichi TAKI

    Editorial Bureau, Senior Staff Writer
    Nikkei Inc.

  • Prof. Dr. Kazutoshi NAKASHIMA, MD, PhD

    Professor
    Department of Health Science, Faculty of Sports and Health Science,
    Daito Bunka University

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Mr. Yoshihide HIRUTA

    Director of International Cooperation, International Business Management, Global Management
    Sysmex Corporation

  • Prof. Dr. Izuru MAKIHARA

    Professor
    Research Center for Advanced Science and Technology, University of Tokyo

  • Prof. Noboru MINAKAWA Ph.D.

    Institute of Tropical Medicine, Nagasaki University
    Professor,

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Mr. Hisahiko YANO

    Senior Staff Writer Editional Bureau
    Nikkei Inc.

  • Dr. Richard H. KASZYNSKI

    Co-founder and Director
    Stanford Solutions, Stanford Medical School

  • Mr. Michael PEEL

    Executive editor
    Nikkei Asia

17:20-18:20

Conclusion/Statementステートメント策定

Click here for a list of discussers

  • Dr. Kazunari ASANUMA, MD, PhD

    Senior Assistant Minister for Health Security and Technology,
    Minister's Secretariat,
    Ministry of Health, Labour and Welfare

  • Dr. Akifumi IMAMURA, M.D.

    Director
    Department of Infectious Diseases
    Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

  • Prof. Yoko URYUHARA, MBA, PhD

    Associate Professor,
    Faculty of Commerce, Doshisha University
    Director, Social Marketing Research Centre

  • Dr. Shigeru OMI, MD, PhD

    President of JAPAN Community Health care Organization (JCHO) Regional Director Emeritus,
    World Health Organization (WHO), Regional Office for Western Pacific

  • Prof. Dr. KANO Mitsunobu, MD/PhD

    Vice Executive Director and Professor
    Okayama University
    Council Member, Science Council of Japan
    Science and Techonology Co-Advisor to the Minister of Foreign Affairs of Japan

  • Prof. KITA Kiyoshi

    Dean and Professor,
    School of Tropical Medicine and Global Health,
    Nagasaki University

  • Mr. Michikazu KOSHIBA

    MITSUBISHI UFJ RESEARCH AND CONSULTING CO., LTD.
    Head, Center on Global Health Architecture/General Manager, Social Impact Partnership Business Dept.

  • Prof. Nahoko SHINDO, MD, PhD

    Senior Advisor,
    WHO Health Emergencies Programme (WHE),
    World Health Organization

  • Prof. Yasuhiro SUZUKI

    Vice-Rector
    International University of Health & Welfare

  • Mr. Junichi TAKI

    Editorial Bureau, Senior Staff Writer
    Nikkei Inc.

  • Prof. Dr. Kazutoshi NAKASHIMA, MD, PhD

    Professor
    Department of Health Science, Faculty of Sports and Health Science,
    Daito Bunka University

  • Mr. Ryoji NORITAKE

    CEO and Board Member,
    Health and Global Policy Institute (HGPI)

  • Mr. Ryousuke HARADA

    Senior Exective Editor
    Nikkei Inc.

  • Mr. Yoshihide HIRUTA

    Director of International Cooperation, International Business Management, Global Management
    Sysmex Corporation

  • Prof. Dr. Izuru MAKIHARA

    Professor
    Research Center for Advanced Science and Technology, University of Tokyo

  • Prof. Noboru MINAKAWA Ph.D.

    Institute of Tropical Medicine, Nagasaki University
    Professor,

  • Mr. Mitsuru MIYATA

    CEO
    Miyata Institute of Technologies,K.K.

  • Mr. Hisahiko YANO

    Senior Staff Writer Editional Bureau
    Nikkei Inc.

  • Dr. Richard H. KASZYNSKI

    Co-founder and Director
    Stanford Solutions, Stanford Medical School

  • Mr. Michael PEEL

    Executive editor
    Nikkei Asia

18:20-18:30

General Overview総評

Prof. Keizo TAKEMI

Member of the House of Councillors,
Vice-Chairperson, General Assembly of Party Members of the House of Councillors
Chairperson, Special Committee on Global Health Strategy of LDP
Acting-Chairperson, Headquarters for Novel Coronavirus of LDP
Chairperson, Subcommittee on Governance for Infectious Diseases of LDP
WHO Goodwill Ambassador for Universal Health Coverage
Senior Fellow, Japan Center for International Exchange (JCIE)
Visiting Professor at Nagasaki University

topへ戻る